Eiffel's price has strengthened more than 10% over the past week and IMHO both the chart and the technology behind this small cap biotech suggest good prospects for its near future. It operates in an environment where only a handful of competitors worldwide have similar technology (Super Critical Fluid Technology) which presents major pharmaceutical companies with the opportunity to extend the patent life and efficacy of a vast array of drugs e.g. insulin through re-engineering - and thereby save massive $ on new research, expensive trial process etc.
I admit I'm not strong on T/A but would value the opinion of someone who is. Any chartist's thoughts out there on EIF's short - medium term prospects?
TIA, Gupper
EIF
eiffel technologies limited
